Plasmid DNA Manufacturing Market Trends for 2026

The global plasmid DNA manufacturing market was estimated at US$ 3.10 billion in 2026 and is projected to grow to US$ 14.59 billion by 2035, rising at a compound annual growth rate (CAGR) of 18.77% from 2026 to 2035.

Key Takeaways

• The plasmid DNA manufacturing market to cross USD 3.10 billion by 2026.
• Valuation is projected to hit USD 14.59 billion by 2035.
• Estimated to grow at a CAGR of 18.77% starting from 2026 to 2035.
• North America dominated the market share by 44% in 2025.
• Asia Pacific is expected to grow at the fastest rate during the forecast period.
• By product, the viral vector segment held the dominant share of the plasmid DNA manufacturing market in 2025.
• By application, the gene therapy segment accounted for the largest share of the market in 2025.
• By disease, the infectious disease segment dominated the market in 2025.

Plasmid DNA Manufacturing Market: Genetic Modification

The small and circular extra DNA in bacteria and some other microorganisms is called plasmid DNA. During cell division, plasmid DNA makes its copy and passes from one cell to another. This property of plasmid DNA is used by researchers and scientists for genetic modification of viruses, bacteria, and other cells. Plasmid DNA is used in producing vaccines, pharmaceutical proteins, antibodies, hormones, antibiotics, gene therapy, gene transfer, studying genetic disorders, studying the impact of external factors on genetic materials, and so on. DNA plasmid has a lot of applications in healthcare, and with growing demand for pharmaceuticals, antibiotic resistance in pathogens, a growing number of infectious diseases, and cancer, plasmid DNA manufacturing is going to be in high demand in the future.

How can AI Improve the Plasmid DNA Manufacturing Market?

Plasmid DNAs are in high demand and are produced on a large scale. However, using traditional subjective process control causes highly unstable plasmid yields. To mitigate this challenge, the use of artificial intelligence (AI) and machine learning holds great potential. AI is useful in gene editing as it can achieve affordability, precision, and efficiency. Artificial intelligence is also used in designing. Plasmid DNAs for better stability and success. Patient data can be made easy using AI, and the analyzed data can be used to develop precise and personalized gene therapies, which increases the success rate of treatment.

For instance,

• In May 2024, the open-source gene editor OpenCRISPR-1 was created by Profluent, a protein design business that uses artificial intelligence. This shows how the technology may be applied to produce molecules that have the ability to alter human DNA.

Plasmid DNA Manufacturing Market Trends and Future Outlook

Growing demand for gene therapies, vaccines, and cell therapies is increasing plasmid DNA production. Manufacturers are expanding facilities, improving production efficiency, and strengthening quality standards. Better manufacturing processes help reduce costs, increase output, and support commercial-scale production for global healthcare needs across different treatment areas with reliable supply, consistent quality, faster delivery, and stronger market growth over the coming years.

Companies are investing in advanced purification methods, scalable manufacturing systems, and single-use equipment. These improvements increase product consistency, reduce contamination risks, and shorten production timelines. Stronger regulatory compliance and better documentation also help manufacturers meet customer expectations, support global approvals, improve competitiveness, encourage partnerships, and build long-term business confidence across international markets, with steady investment opportunities ahead for suppliers worldwide.

Future market growth will depend on rising clinical research, expanding biopharmaceutical pipelines, and increasing demand for personalized medicines. Contract manufacturing organizations will play an important role by offering flexible production capacity, specialized expertise, faster project delivery, lower operational costs, and broader global customer support for sustainable industry expansion through continuous innovation, collaboration, investment, resilience, efficiency, quality improvements, and worldwide consistency.

Strategic Initiatives

In May 2025, one of the most focused developments that offer life-changing and long-lasting solutions is advanced therapy medicinal products (ATMPs), such as gene therapies for people suffering from complex or rare diseases. Due to factors such as single-administration with great therapeutic results, limited evidence on long-term durability of effects during the launch, and high costs makes their availability is complex and slow. Thus, to make these treatment options more accessible for patients throughout the EU, policymakers are utilizing their efforts.

In April 2025, Congress MP Shashi Tharoor welcomed the Modi government’s vaccination policy. He stated that this is a good example of the private sector stepping up. Thus, making the government able to offer guidance and leverage it as an instrument of Indian diplomacy.

Overview of Transactions for Organic Chemicals and Starch Products

Executive Summary Table

Market Segmentations

Vaccine Demand Drives the Plasmid DNA Manufacturing Market

To boost the immune system, vaccines are highly essential. Plasmid DNA is used to make vaccines for various diseases. A lot of vaccines are given at a young age to ensure protection against various diseases. The growing birth rate is one of the major reasons behind the demand for vaccines. According to the United Nations, 385,000 babies are born each day, which is equivalent to 140 million babies every year, which suggests that every year, around 140 million children need different vaccines to boost immunity. Apart from this, a lot of vaccines are given multiple times, which increases the demand. The growing population and need for immunity boost is going to increase the production of plasmid DNA-based vaccines.

Strict Regulatory Compliance Restraint the Market

Genetic modification raises a lot of ethical concerns because naturally existing genetic material is modified to gain desirable results. Plasmid DNAs are used for inserting and modifying genetic material; therefore, such genetically modified plasmids need to be kept in a highly regulated and controlled environment in order to avoid the risk of losing GMOs in nature. This leakage of GMOs in nature can genetically modify the naturally existing organisms, leading to a huge biothreat. Therefore, governments on national and international levels have very strict regulatory systems to avoid any biothreat. To follow the regulations, extra efforts, time, resources, money, and energy are invested, which becomes a restraining factor for the plasmid DNA manufacturing market.

Demand for Plasmid DNA will Increase due to Rising Cancer Cases

Cancer is a growing concern and poses a financial burden on the healthcare system. According to the WHO, in 2022, 20 million new cancer cases were anticipated, and by 2050, it is estimated that there will be more than 35 million new cancer cases, which is a 77% increase when compared to 2022. Due to the rise in cancer cases, new plasmid-based therapies are being developed. Plasmid vaccines, gene therapy, and cell therapy are some of the therapies in which plasmids are used. Plasmid DNA also provides the opportunity to develop personalized therapeutics. With the growing use of monoclonal antibodies in cancer treatment, the use of plasmid DNA for making monoclonal antibodies is also increasing.

Market Segmentations

Which Product Segment Dominated the Plasmid DNA Manufacturing Market?

By product, the viral vector segment held the dominant share of the market. Viral vectors are used in cell & gene therapies and vaccine administration. Viral vectors are in demand due to their high efficiency in delivering genetic information and excellent targeted delivery of bioactive molecules. Currently, 2-3 billion liters of bioreactor capacity every year is needed for the production of viral vectors, and in the future, the capacity is going to increase even further.

For instance,

• In March 2024, With the recent release of the ground-breaking RepCap plasmid pPLUS® AAV-RC2, a member of the Sartorius group and a well-known upstream solutions provider for biologic, cell, and gene therapy production, Polyplus, it is now possible to manufacture Adeno-associated viral vector 2 (AAV2). This launch significantly expands Polyplus's product line and advances the company's strategic objective of being a leading provider of vital raw materials for the production of autonomous aerial vehicles (AAVs).
• In August 2022, In order to create purification membranes for the large-scale production of viral vectors and virus-like particles in the future, researchers at the University of Arkansas and two partner universities have been granted a $6 million grant by the National Science Foundation (NSF).

Why Did the Gene Therapy Segment Dominate the Plasmid DNA Manufacturing Market?

By application, the gene therapy segment accounted for the largest share of the plasmid DNA manufacturing market in 2023. Gene therapies are used to fix, replace, and remove genes that cause health issues. Researchers are showing interest in gene therapy due to its potential in treating cancer, rare diseases, and genetic disorders. The number of clinical trials has significantly increased in the last decade. According to the National Institutes of Health, there are more than 5000 gene therapy trials listed with them as of 2023.

For instance,

• In June 2024, ProBio Inc. is a New Jersey-based contract development and manufacturing organization (CDMO) that recently opened a state-of-the-art facility in Hopewell. The company also revealed that it has expanded its production capabilities for viral vectors and plasmid DNA. ProBio’s new, state-of-the-art facility, which will serve as the hub for its operations in the area, will play a major role in helping North America provide life-altering cell and gene treatments.

How the Infectious Disease Segment Dominated the Plasmid DNA Manufacturing Market?

By disease, the infectious disease segment dominated the plasmid DNA manufacturing market in 2023. Plasmid DNA is used for developing vaccines for infectious diseases. A lot of infectious diseases are highly contagious and can lead to a pandemic like the COVID-19 pandemic. Hence, developing vaccines for infectious diseases is highly needed, and vaccines can be developed using plasmid DNA. Plasmid DNA-based vaccines hold high value in cases where conventional vaccines fail.

For instance,

• In February 2023, in Marburg, Germany, BioNTech SE declared the opening of its first proprietary plasmid DNA production plant. In order to produce plasmid DNA for commercial goods and clinical product candidates in the fields of infectious illnesses and cancer, BioNTech intends to operate autonomously.

Regional Analysis

Growing R&D Promotes North America’s Market

By region, North America dominated the plasmid DNA manufacturing market share by 44%. North America leads in research and development associated with healthcare, pharmaceutical, and biotechnology industries. Governments, organizations, healthcare systems, and research institutions contribute to developing new and innovative procedures and products to improve healthcare facilities. With growing cases of cancer, infectious diseases, and genetic disorders, North America has accelerated the research. The government also invests and launches programs to encourage companies to take the initiative. Apart from this, major market players collaborate with each other or government institutions to make collaborative efforts for better results. 

U.S. Plasmid DNA Manufacturing Market Trends

The U.S. dominated the plasmid DNA manufacturing market, followed by Canada and North America. The U.S. has advanced technology, better facilities, and resources that help professionals to provide high-quality results. The major players in the U.S. not only supply plasmid DNA but also export the products on a global level, which gives a strong boost to the growth of the market in the U.S. The U.S. also has a strong presence in the healthcare system and the biotech and pharma industry, which uses plasmid DNA for a lot of different purposes.

Apart from this, there is a growing number of cancer and genetic disorders that may need gene therapy. According to research published in 2023 by NIH, it is expected that there will be 1.09 million cancer patients who will receive gene therapy by 2034. It is estimated that the number of patients who are going to be treated with gene therapy in the year 2025 will be 95,696.

Canada Market Trends

Canada's plasmid DNA manufacturing market is growing because of increasing investment in biotechnology research, expanding clinical trials, and strong government support for life sciences. Rising demand for gene therapies, vaccines, and advanced biologic medicines is encouraging companies to increase local manufacturing capacity. Partnerships between research institutions and manufacturers are improving innovation. Better production technologies and skilled professionals are also helping strengthen domestic manufacturing capabilities and global competitiveness.

Growing Biotechnology Industry Drives Asia Pacific’s Market

By region, Asia Pacific is expected to grow at the fastest rate during the forecast period. The biotechnology industry is the main user of plasmid DNA. The government and many organizations in Asia Pacific have analyzed the potential of biotechnology in the growth of the region, which is why they are heavily investing in the biotechnology industry. This investment has positively impacted the growth of the plasmid DNA manufacturing market. China, India, and Japan significantly contribute to the growth of the market. The growing population in India and China also promotes that market growth because vaccines and other therapeutics will be needed in large amounts.

China Plasmid DNA Manufacturing Market Trends

In China, urbanization and an aging society are going to demand quality health. It is estimated that there will be 400 million people aged 60 years or above age by 2030. China is highly invested in developing better healthcare solutions, and the government and organizations have taken various initiatives.

India Plasmid DNA Manufacturing Market Trends

The biotechnology industry is also growing strongly in India, which is increasing the use of plasmid DNA for developing vaccines and other therapeutics. When it comes to the size of the Indian biotechnology industry, it holds the 12th position at the global level and the 3rd position in the Asia Pacific. There are more than 800 core biotech companies in India. Some of the factors that have contributed to the growth of the plasmid DNA manufacturing market include the largest production and supply of BCG, DPT, and measles vaccines, the developed world’s first DNA vaccines for COVID-19, and the 2nd highest number of manufacturing plants approved by USFDA.

Europe Backed by Research and Government Support

Europe is expected to grow significantly in the plasmid DNA manufacturing market during the forecast period. Europe is experiencing a rise in the research conducted by the institutes as well as industries. At the same time, the rising demand for the treatment of rare diseases is also increasing. Thus, along with these factors, the government is also providing its support, which in turn promotes the market growth.

UK Plasmid DNA Manufacturing Market Trends

The industries in the UK are focusing on enhancing the production rates of plasmid DNA treatment options to deal with the rising demand for the treatment of rare diseases. Furthermore, new research carried out in industries and institutes is also contributing to the same. They are further supported by the investments or funding provided by the government.

The increasing number of research in industries, along with the institutes, is driving the market. At the same time, this is also increasing the collaboration between them. Moreover, to make these treatment options affordable government is also contributing, along with the help of technological advancements.

Germany Market Trends

Germany's plasmid DNA manufacturing market is expanding due to its strong pharmaceutical industry, advanced research infrastructure, and increasing focus on biotechnology innovation. Growing development of gene therapies, cell therapies, and vaccines is creating higher demand for reliable plasmid DNA production. Companies are investing in modern manufacturing facilities and quality systems. Collaboration between universities, research organizations, and biopharmaceutical companies is supporting continuous product development and manufacturing growth.

Top Companies’ Revenue Info.

• Twist Bioscience provides a proprietary semiconductor-based synthetic DNA manufacturing process using a high-throughput silicon platform, offering high precision and high-quality gene fragments. The company generated a revenue of $96.1 million in the third quarter of FY2025, an increase of 18%. (Source: https://investors.twistbioscience.com/news-releases/news-release-details/twist-bioscience-reports-fiscal-second-quarter-2024-financial)
• Charles River Laboratories provides a comprehensive suite of plasmid DNA manufacturing services to support preclinical research studies to clinical development, and commercial manufacturing. The fourth-quarter 2024 revenue was $1 billion, and the full-year 2024 revenue was $4.05 billion.

Latest Announcement by Industry Leaders

In April 2025, ProBio launched a GMP Plasmid DNA manufacturing service at Hopewell, NJ. Allen Guo, CEO of ProBio, commented that the company understands pharmaceutical companies’ concerns about unpredictable timelines of plasmid DNA manufacturers. The company is committed to raising the bar for the industry and will deliver at the speed drug developers serve.

Recent Developments in the Plasmid DNA Manufacturing Market

• In December 2025, Twist Bioscience Corporation launched research-grade Plasmid DNA Preps to accelerate pre-clinical drug discovery and development. “Our new plasmid preps combine the quality and consistency needed for preclinical research with the speed and cost efficiency customers have come to expect from Twist,” said Emily M. Leproust, CEO and co-founder of Twist Bioscience.
• In August 2025, Bionova Scientific, an Asahi Kasei subsidiary and biologics CDMO, officially opened a 10,000-square-foot plasmid DNA (pDNA) development and production facility in The Woodlands, Texas. Announced on August 12, 2025, this strategic expansion strengthens the U.S. advanced therapeutics supply chain. The new site focuses on designing, developing, and manufacturing research-grade pDNA materials to support the rapidly growing cell and gene therapy (CGT) sector.

Top Companies in the Plasmid DNA Manufacturing Market

• VGXI, Inc.
• Bionova Scientific
• Asahi Kasei
• Catalent Pharma Solutions
• JAFRAL Ltd.
• Vigene Biosciences
• Charles River Laboratories
• Luminous Biosciences
• Nature Technology Corporation
• Plasmidfactory GmbH
• Aldevron
• PackGene
• Cobra Biologics & Pharmaceutical Services
• Akron Biotech
• Delphi Genetics
• AGC Biologics
• Thermo Fisher Scientific

Innovation by Bionova in the Plasmid DNA Manufacturing Market

Innovation by Thermo Fisher in the Plasmid DNA Manufacturing Market

Segments Covered in the Report

By Product

• Viral Vectors
• Plasmid DNA
• Non-Viral
• Electroporation
• Lipid/Polymer
• Nanoparticles
• Others

By Application

• Gene Therapy
• DNA Vaccines
• Immunotherapy
• Others

By Disease

• Infectious Disease
• Cancer
• Genetic Disorder
• Segments Covered in the Report

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait